Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis

被引：1
|
作者：
Sandborn, William J.
Van Assche, Gert A.
Reinisch, Walter
Colombel, Jean-Frederic
D'Haens, Geert R.
Wolf, Douglas C.
Kron, Martina
Tighe, Mary Beth
Lazar, Andreas
Thakkar, Roopal
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S123 / S124
页数：2
相关论文
共 50 条
  • [1] Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis
    Sandborn, William
    Van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas
    Kron, Martina
    Tighe, Mary
    Lazar, Andreas
    Thakkar, Roopal
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S3 - S4
  • [2] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Warner, Ben
    Harris, Adam W.
    [J]. GASTROENTEROLOGY, 2012, 143 (01) : E42 - E42
  • [3] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas C.
    Kron, Martina
    Tighe, Mary Beth
    Lazar, Andreas
    Thakkar, Roopal B.
    [J]. GASTROENTEROLOGY, 2012, 142 (02) : 257 - +
  • [4] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Feagan, Brian G.
    Schreiber, Stefan
    Wolf, Douglas C.
    Axler, Jeffrey L.
    Kaviya, Arpeat
    James, Alexandra
    Curtis, Rebecca I.
    Geransar, Parnia
    Stallmach, Andreas
    Ehehalt, Robert
    Bokemeyer, Bernd
    Khalid, Javaria Mona
    O'Byrne, Sharon
    [J]. INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) : 1028 - 1035
  • [5] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [6] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    [J]. FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [7] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    O'Connor, Donal B.
    Lahiff, Conor
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 93
  • [8] Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Feagan, Brian G.
    Marano, Colleen
    Zhang, Hongyan
    Strauss, Richard
    Johanns, Jewel
    Adedokun, Omoniyi J.
    Guzzo, Cynthia
    Colombel, Jean-Frederic
    Reinisch, Walter
    Gibson, Peter R.
    Collins, Judith
    Jarnerot, Gunnar
    Hibi, Toshifumi
    Rutgeerts, Paul
    [J]. GASTROENTEROLOGY, 2014, 146 (01) : 85 - 95
  • [9] Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
    Midha, Vandana
    Mahajan, Ramit
    Mehta, Varun
    Narang, Vikram
    Singh, Arshdeep
    Kaur, Kirandeep
    Sood, Ajit
    [J]. INTESTINAL RESEARCH, 2018, 16 (01) : 83 - 89
  • [10] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY
    Sands, Bruce E.
    Schreiber, Stefan
    Lirio, Richard A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 93 - 94
12345